DePuy Synthes Acquires Gemtrack RF Tracking: J&J Orthopedics Strategy, VELYS Platform Evolution, and the $12.7B Orthopedic Robotics Market

At a Glance: The DePuy Synthes-Gemtrack Agreement

On May 26, 2026, DePuy Synthes, the orthopedics division of Johnson & Johnson, announced a definitive agreement to acquire selective rights to develop, manufacture, and commercialize Gemtrack technology from MinMaxMedical (MMM), a Grenoble, France-based pioneer in surgical innovation. The deal brings miniature radiofrequency (RF) tracking technology to DePuy Synthes's VELYS Enabling Tech Portfolio for use across shoulder, hip, and knee joint reconstruction, in both navigation and robotic-assisted surgery applications.

The Technology: What Gemtrack Changes

Current Limitations: Optical Tracking in Orthopedic Robotics

Today's orthopedic navigation and robotic-assisted surgery systems overwhelmingly rely on optical tracking technology. Systems like the VELYS Robotic-Assisted Solution, Stryker's Mako, and Zimmer Biomet's ROSA use infrared cameras to track reflective arrays attached to bones, instruments, and robotic arms. This approach, while proven and accurate, introduces several operational constraints:

• Line-of-sight dependency: The infrared camera must maintain an unobstructed view of all tracking arrays throughout the procedure. Any obstruction — a surgical assistant's hand, a drape, patient positioning equipment — can interrupt tracking
• Operating room footprint: Infrared camera systems require physical space and specific positioning, contributing to crowded OR setups
• Invasive fixation: Tracking arrays must be rigidly fixed to the patient's anatomy using invasive pins or anchors, creating additional surgical steps and potential morbidity
• Environmental sensitivity: Bright light sources (surgical lights, sunlight) and highly reflective objects can interfere with optical tracking
• Workflow friction: The surgical team must constantly manage camera positioning and line-of-sight throughout the procedure

Gemtrack's RF-Based Approach

Gemtrack uses radiofrequency signals rather than infrared light for position tracking. This fundamental technology shift eliminates the line-of-sight requirement and introduces several potential advantages:

The technology has the potential to:

1. Eliminate the need for infrared cameras entirely
2. Reduce or eliminate invasive pins and anchors used for array fixation
3. Enable continuous, highly accurate real-time tracking regardless of surgical positioning
4. Simplify OR setup and improve surgical workflow
5. Reduce the overall footprint of navigation/robotic systems

MinMaxMedical and the Orthotaxy Connection

MinMaxMedical was founded by Stéphane Lavallée, a serial entrepreneur in surgical technology whose previous company, Orthotaxy, was acquired by Johnson & Johnson in 2018 and became the foundation of the VELYS robotic platform. This long-standing relationship provides DePuy Synthes with deep familiarity with Lavallée's technology development approach and increases confidence in the integration path.

MMM itself holds numerous patents in AI-based imaging, augmented reality, and next-generation robotics, making this more than a single-technology acquisition — it is a partnership with a deep innovation pipeline.

VELYS Platform: Current State and Strategic Evolution

VELYS Portfolio Overview

The VELYS platform is DePuy Synthes's connected ecosystem of digital and robotic technologies for orthopedic surgery. The current portfolio includes:

The VELYS Robotic-Assisted Solution for total knee arthroplasty is an imageless system — it does not require a preoperative CT scan, which reduces preoperative preparation time, cost, and radiation exposure. It is designed exclusively for use with the ATTUNE Knee System.

Market Share Trajectory

According to GlobalData analysis, DePuy Synthes VELYS has experienced rapid market share growth:

• 2021: VELYS entered the orthopedic robotics market for TKA indications
• 2022: Market share grew from less than 10% to over 20%
• Key driver: VELYS is 56% cheaper than Stryker Mako, with service costs approximately 40% lower

This competitive pricing strategy has accelerated adoption, particularly among ambulatory surgery centers and community hospitals where capital budgets are more constrained.

Gemtrack Integration: The Next Phase

Pending successful product development and regulatory approvals, Gemtrack will be integrated across the VELYS platform. Namal Nawana, Worldwide President of DePuy Synthes, stated: "This new collaboration will be applied broadly to the VELYS ecosystem to reduce the reliance on line-of-sight dependent navigation and offering the potential for improved navigation precision."

The integration strategy likely involves:

1. Near-term: Incorporating RF tracking into next-generation VELYS knee systems
2. Medium-term: Extending RF tracking to hip and shoulder applications (expanding the addressable market)
3. Long-term: Enabling new surgical techniques and approaches that were previously constrained by optical tracking limitations

J&J's DePuy Synthes Separation: Context for the Gemtrack Deal

The October 2025 Announcement

In October 2025, Johnson & Johnson announced its intent to separate the DePuy Synthes orthopedics business into a standalone company, to be completed within 18 to 24 months. The stated rationale was to:

• Enhance strategic and operational focus for each entity
• Enable DePuy Synthes to operate with greater agility as an independent company
• Allow J&J to sharpen focus on higher-growth MedTech segments (cardiovascular, surgery, vision)
• Create the "largest, most comprehensive orthopaedics-focused company" with leading market share positions

J&J CEO Joaquin Duato framed the separation as portfolio optimization: "This transaction enables Johnson & Johnson to further strengthen its focus and investment toward higher-growth areas where we can meaningfully extend and improve patient lives."

The February 2026 Sale Exploration

In February 2026, Reuters and Bloomberg reported that J&J was preparing financial materials for a potential outright sale of DePuy Synthes, rather than a spinoff. Key details:

• Bloomberg Intelligence estimated the unit's value at approximately $20 billion, or $28 billion including debt
• Private equity firms were identified as the most likely buyers, with several large PE firms reportedly considering joint bids
• CFO Joe Wolk indicated J&J was exploring multiple separation paths, with a tax-free spinoff as the primary focus but remaining open to alternatives
• No further material updates were expected before mid-2026

Why the Gemtrack Deal Matters Strategically

The Gemtrack acquisition takes on additional significance in the context of a potential sale or spinoff:

1. Technology premium: Proprietary RF tracking technology that no competitor currently offers increases the standalone value of DePuy Synthes
2. Platform differentiation: Eliminating the VELYS platform's dependence on optical tracking creates a unique selling proposition versus Mako, ROSA, and CORI
3. Market expansion: RF tracking enables VELYS to extend into shoulder applications, addressing a growing market segment where Zimmer Biomet and Stryker are also developing robotic solutions
4. IP portfolio: The MMM patents and know-how add valuable intellectual property to the standalone entity
5. Revenue potential: A differentiated technology platform could command premium pricing and accelerate market share gains, improving the financial profile of the separated business

Orthopedic Robotics Market: Competitive Landscape

Market Size and Growth

The global orthopedic robotic surgery market is experiencing rapid expansion:

Despite variation in estimates, all sources agree on double-digit growth driven by:

• Rising orthopedic procedure volumes (aging population, osteoarthritis)
• Increasing adoption of robotic-assisted surgery
• Technological innovation (AI, improved navigation, smaller systems)
• Expansion into ambulatory surgery centers
• Growing evidence base supporting improved outcomes

North America commands approximately 42–45% of the global market, with the U.S. alone accounting for approximately $695.5 million in 2024 revenue.

Major Competitors

Competitive Dynamics

The orthopedic robotics market is becoming less about the presence or absence of a robotic arm and more about the ecosystem surrounding it. Companies are competing on:

• System cost and total cost of ownership: VELYS's 56% price advantage over Mako is a significant competitive lever
• Workflow efficiency: Reducing setup time, line-of-sight management, and overall OR complexity
• Platform breadth: The ability to serve multiple anatomical sites (knee, hip, shoulder, spine) from a single platform
• Data and analytics: Intraoperative data collection and post-surgical analytics
• Implant ecosystem integration: Exclusive pairing between robotic platforms and implant systems (VELYS-ATTUNE, Mako-Triathlon/Restoris)

Gemtrack's RF tracking technology, if successfully commercialized, would represent a potential generational leap in platform differentiation — the first orthopedic system to eliminate optical line-of-sight requirements entirely.

Regulatory Pathway for RF Surgical Tracking

FDA Classification and Clearance

Surgical navigation and tracking technologies are typically regulated as Class II medical devices, cleared through the 510(k) pathway. For Gemtrack specifically, the regulatory strategy will likely involve:

1. Establishing substantial equivalence to existing surgical navigation systems that use optical tracking
2. Demonstrating equivalent or superior accuracy through bench testing and potentially clinical data
3. Addressing electromagnetic compatibility (EMC) considerations, as RF systems must coexist with other electronic equipment in the OR
4. Software validation under IEC 62304 for the tracking algorithms and integration with the VELYS platform

EU MDR Considerations

Under the EU Medical Device Regulation, surgical navigation systems are classified as Class IIb devices, requiring conformity assessment by a Notified Body. The integration of RF tracking technology into an existing platform will likely require:

• Updated technical documentation reflecting the new tracking modality
• Clinical evaluation data demonstrating equivalent or improved performance
• Risk management file updates per ISO 14971
• Potential post-market clinical follow-up (PMCF) requirements

Timeline

DePuy Synthes stated that "additional program milestones and timing will be released as development and regulatory pathways advance." Given typical development and regulatory timelines for surgical navigation enhancements, commercial availability of Gemtrack-integrated VELYS systems is likely 2–3 years from the announcement date.

Implications for Industry Stakeholders

For Orthopedic Surgeons

RF tracking technology, if successfully developed and commercialized, could meaningfully simplify the workflow of robotic-assisted joint replacement. Eliminating line-of-sight constraints and reducing the need for invasive pin fixation would address two of the most commonly cited frustrations with current navigation systems.

For Hospital and ASC Administrators

A smaller-footprint, less complex robotic system that does not require dedicated OR space for camera equipment could lower the barriers to adoption, particularly for ambulatory surgery centers where OR size and setup time are critical factors.

For Competitors

Stryker, Zimmer Biomet, and Smith+Nephew will need to consider whether to develop competing RF tracking capabilities, form partnerships, or maintain their optical tracking approaches. The competitive response could drive a new cycle of innovation in surgical navigation.

For the Investment Community

The Gemtrack acquisition should be viewed as both a technology investment and a strategic asset-building exercise ahead of the DePuy Synthes separation. Proprietary, differentiated technology strengthens the standalone value proposition, whether the separation takes the form of a spinoff or a sale.

Key Takeaways

1. Technology breakthrough: Gemtrack's miniature RF tracking eliminates the line-of-sight dependency that constrains every current orthopedic navigation and robotic system
2. Strategic timing: The acquisition bolsters DePuy Synthes's technology portfolio ahead of J&J's planned separation, potentially increasing standalone value beyond the estimated $20 billion
3. Platform differentiation: RF tracking integration into VELYS could establish a new industry standard, creating first-to-market advantage in joint reconstruction navigation
4. Market growth tailwind: The orthopedic robotics market is projected to grow at 14–17% CAGR through 2034, providing a substantial opportunity for technology differentiation
5. Developer pedigree: Stéphane Lavallée's track record with Orthotaxy (now VELYS) increases confidence in successful development and commercialization of Gemtrack technology
6. Competitive impact: If successful, Gemtrack could force Stryker, Zimmer Biomet, and Smith+Nephew to respond with their own next-generation tracking solutions, accelerating innovation across the sector